Hepatic Arterial Therapy with Drug-Eluting Beads in the Management of Metastatic Pancreatic Carcinoma to the Liver: A Multi-Institutional Registry

Table 1

Clinical demographics for liver dominant metastatic pancreatic cancer DEBIRI-treated patients.

Characteristics	𝑁=10
Pancreatic primary
Pancreatic adenocarcinoma; Neuroendocrine	6; 4
Age (years) (median, range)	(69, 45–77)
Body mass index (median, range)	23.8 (16.6–32.3)
Gender
Male; Female	4; 6
Past medical history
Cardiac; Vascular; Pulmonary; Diabetes; Insulin; Non-insulin; Alcohol; Tobacco; Median pack year smoking; Hypertension; Prior cholecystectomy	0; 0; 1; 3; 2; 1; 1; 2; 40; 5; 2
Karnofsky Performance Scale, median % (range)	100 (80–100)
Extent of liver lesions
Distinct number; Numerous	6; 4
Liver involvement
<25%; 26–50%	7; 3
Number liver tumors (median, range); 1; 2; ≥3	(2, 1–3); 1; 4; 5
Sum of target lesion(s) size (median, range)	3.9 cm (1–10)
Extrahepatic disease; Para-aortic lymph node; Lung, adrenal; Pancreatic primary	3; 1; 1; 1
Lesion location
Seg 2–4; Seg 4–8; Seg 5–8; Other	0; 1; 3; 6